Breast Implant-Associated Cancers: Understanding BIA-ALCL, SCC and New Changes

Breast implant associated cancers are not one disease. Breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, is a rare cancer of immune cells, with a well-established association with textured implants. Squamous cell carcinoma, or SCC, and other cancers have also been reported around implants, but important questions about their causes and risks remain unanswered. These conditions are distinct from ordinary breast cancer. The practical message is to have new implant-related changes assessed, without assuming that every change is cancer or that everyone needs implant removal.

1. What Are the Different Cancer Concerns?

A breast implant sits within a layer of scar tissue called a capsule. This is the body's response to an implanted device. The capsule and any fluid around the implant are different from the breast tissue itself. That distinction helps explain why an implant-associated cancer may require a different investigation from a typical breast lump.

These names are not interchangeable. In particular, the FDA's reports of other lymphomas do not mean that every lymphoma around an implant is BIA-ALCL. Identifying the actual cell type matters.

2. What Is Known About BIA-ALCL and Implant Texture?

The US Food and Drug Administration, or FDA, states that BIA-ALCL risk is higher with textured-surface implants than with smooth-surface implants. Texture describes the outer shell, not whether the implant contains saline or silicone gel. Both fill types have a silicone outer shell.

This does not support treating all implant surfaces as having identical risk. It also does not justify promising that a particular implant makes every cancer concern impossible. Information about the full implant history matters, especially if someone has had replacements or a temporary tissue expander during reconstruction.

A tissue expander is a temporary device used to stretch tissue before a later implant operation. The FDA has identified concerns about certain textured expanders, while noting limited information about the risk associated with temporary exposure.

For BIA-ALCL, the FDA says implant fill does not appear to be a risk factor, but also explains that the question has not been evaluated in a large, well-designed epidemiological study. Saline versus silicone is therefore not a substitute for understanding surface type and device history.

3. SCC and Other Reports Carry Different Uncertainties

The FDA's SCC safety communication was issued on March 8, 2023, and updated on March 22, 2023. Its broader implant-complications page displays a December 14, 2023 update. These are regulatory safety resources, not three independent studies confirming the same outcome.

The SCC communication describes cancers found in implant capsules and reports of deaths from disease progression. It says these occurrences may be rare, while emphasizing that their cause, frequency and risk factors remain unknown. Reports include both smooth and textured implants and both saline and silicone fill. That does not establish equal risk across those categories.

Passive safety reports are useful warning signals, but they cannot establish incidence by themselves. Reports may be incomplete, duplicated or missing altogether, and the reporting system lacks a reliable count of the population at risk. Dividing reports by an unrelated estimate of implant procedures would not produce a trustworthy personal risk estimate.

The appropriate conclusion is neither that every reported cancer was caused by an implant nor that uncertainty makes the reports unimportant. These findings justify awareness, careful assessment and continued investigation.

4. Changes That Need Clinical Assessment

Persistent swelling, a new lump or pain near an implant are important BIA-ALCL symptoms. Changes may appear years after surgery, long after the incision has healed. Assessment may reveal a seroma, meaning a fluid collection around the implant, or new hardening of the capsule.

UK regulator guidance also notes that swelling can be painless. Pain is therefore not required before seeking advice. In the FDA's SCC literature review, reported symptoms included swelling, pain, lumps and skin discoloration.

• Contact your surgeon or another healthcare professional promptly about new or persistent swelling.
• Arrange assessment of a new breast or implant-area lump, unexplained pain or new firmness.
• Report unexpected changes in breast size, shape, feel or skin appearance.
• Explain when the change began and whether it is progressing.

These findings do not diagnose cancer. Implant problems such as rupture, capsular contracture and infection can also cause changes. Capsular contracture means that scar tissue tightens around the implant. Ordinary breast conditions remain possible too.

The symptom list is not a rule-out checklist. A change that is not listed can still deserve assessment. Conversely, having one of these symptoms does not identify which condition is responsible. The purpose of seeking care is to distinguish the possibilities.

5. How Specialist Assessment Works

5.1 Examination and Imaging

Assessment starts with the history of the change, the implant history and a clinical examination. When BIA-ALCL is suspected, diagnostic guidance commonly uses ultrasound first to look for fluid, a mass or abnormal nearby lymph nodes. Other imaging may be appropriate depending on the findings.

This is a targeted investigation of a clinical concern, not a universal scan that establishes whether someone has any possible implant-associated cancer.

5.2 Fluid or Tissue Examination

If there is suspicious fluid or a mass, the team may arrange sampling for pathology, which is laboratory examination of cells or tissue. For suspected BIA-ALCL, this includes looking at cell appearance and appropriate markers, including CD30 and ALK. A marker result needs specialist interpretation alongside the other findings.

Different suspected cancers require different laboratory assessment. A test directed at BIA-ALCL is not automatically a test for SCC or every other malignancy. The FDA advises clinicians evaluating implant-related specimens to characterize all findings and potential diagnoses.

5.3 Expert Review When Findings Are Unclear

Specialist input is important when symptoms, imaging and pathology do not fit together. UK diagnostic guidance recognizes that persistent concern after a negative assessment may require further investigation or referral. A reassuring result should be interpreted in the context of the whole assessment, rather than treated as an answer to every future change.

If cancer is confirmed, care should be coordinated by professionals experienced in the specific diagnosis. This may involve breast or plastic surgery, radiology, pathology and cancer specialists. Evaluation before elective implant surgery matters because a confirmed diagnosis can change the operation that is appropriate.

6. What Should People Without Symptoms Do?

In the United States, the FDA does not recommend routine implant removal in people without symptoms solely because of BIA-ALCL concerns. Its SCC communication likewise does not recommend removal solely because of concern about SCC or the other reported lymphomas in someone without symptoms. It advises continuing routine medical care and follow-up.

The UK Medicines and Healthcare products Regulatory Agency, or MHRA, also advises that implants do not need to be removed in the absence of symptoms associated with BIA-ALCL. This is independent regulatory guidance, not a separate outcome study.

No recommendation for routine removal should be interpreted as a guarantee of zero risk. It means that awareness and appropriate follow-up, rather than automatic surgery for everyone, are the regulator's advice.

Keep three purposes separate: ordinary breast-cancer screening, checks for implant integrity such as silicone rupture, and investigation of new symptoms. An ultrasound or MRI used to check for rupture is not a universal cancer-clearance test. Continue the follow-up appropriate to your device and your individual breast-health circumstances.

If you are considering removal despite having no symptoms, ask about the potential benefits, limitations and surgical risks, including whether capsule removal is indicated. Implant removal and capsulectomy, meaning removal of capsule tissue, are not identical procedures. The decision needs individual clinical advice rather than a blanket recommendation.

7. Records and Questions That Make a Consultation More Useful

Keep your implant device card if available. The FDA recommends retaining the manufacturer and model information. If these are missing, ask the original surgeon or surgical facility for the operative record. Device cards may also identify the style, serial or lot number and size.

Try to assemble a history of previous implants, replacements and tissue expanders, not just the devices currently in place. Bring earlier imaging or pathology reports if you have them. Do not postpone assessment of a new change while waiting for complete paperwork.

• What are my current and previous implant surfaces, manufacturers and models?
• Could this change reflect an implant complication, a breast condition or a capsule-associated cancer?
• What question will each proposed scan or laboratory test answer?
• Will fluid or tissue need review by a pathologist familiar with implant-associated cancers?
• If the initial results are reassuring but the change persists, what is the follow-up plan?
• If surgery is being considered, should diagnostic assessment happen first?

The central distinction is between an established, texture-related association for BIA-ALCL and the greater uncertainty surrounding SCC and other reports. Neither panic nor dismissal is helpful. Know your device history, continue appropriate care and have new breast or implant changes assessed.